* Pfizer & Mylan are planning to merge the Meridian Medial Technologies Unit of Pfizer into new generics business. Note that, this unit currently produces Mylan’s EpiPens.
* Both companies are actively involved in discussions for arranging a considerable supplement for the broader deal. The Upjohn division of Pfizer will be merged to Mylan; however, the terms and conditions for this step are not yet finalized.
* The final decision regarding the same might be taken before the closure of Upjohn-Mylan merger in the year 2020. After that, you can expect more EpiPen coupons.
Reports reveal that Pfizer is currently struggling hard to produce a regulated supply of EpiPen auto-injectors. It is expected that moving Meridian to a whole new business may take away the headache from Pfizer. A few months back, the company also had a deal with the Food and Drug Administration about using EpiPens even after four months of their expiration dates.
People who are suffering from severe allergic reactions consider EpiPens as lifesaver solutions. Schools and parents prefer to stock them on a routine basis so that they can have a reliable option for treatment when kids experience allergies. The shortage in supply of EpiPens has become a serious issue for all age groups in the United States.
In order to deal with the shortage, many newcomers in the industry are also trying to present their solutions over EpiPens and Symjepi from Sandoz is one of the most popular examples for this. Many other companies are also trying to find solutions to deal with EpiPen Shortage, and they are also interested in providing Epipen coupon.
After the merger, the new Mylad/Pfizer company would have a well-regulated stream of EpiPens and the issues related to the shortage, and limited production can be addressed with ease. At the same time, this new branch will be able to ensure proper supply of many other off-patent drugs from Pfizer such as Viagra (Sildenafil), Lyrica (Pregabalin) and Lipitor (Atorvastatin). In short, patients will be able to have easy access to all essential medications to deal with medical emergencies. It will also handle the EpiPen Shortage very well.
The plan for this new merger was recently announced by Mylan and Pfizer; however, the majority of shares for this new generic company will be held by Pfizer. They may also offer new Epipen coupon in the near future.
Analysts in the industry said that this merger could offer a lifeline to Mylan, but they have some serious questions regarding long term growth aspects. Stats reveal that Mylan is undergoing huge competition in the market, and the sales are also sliding from the past few months. However, Upjohn’s have obtained huge benefits due to several off-patent products. In this scenario, the long-term plans of the new generic company and Mylan are a matter of prime attention.
Pfizer and Mylan also revealed that they are expecting the estimated cost saving of $1 billion by the year 2024 with this new merger of Upjohn and Mylan. The chances are that the deals between both companies will close in the middle of the coming year. They are currently waiting for the votes from Mylan Shareholders and regulatory teams. Once all terms and conditions are finalized, we can expect some positive steps in the direction of EpiPen Shortage.